A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell diseaseJulia Xu, Swee Lay Thein, Laurel A. Menapace et al.|Blood|2022Cited by 72
Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation StudyJulia Xu, Swee Lay Thein, Anna Conrey et al.|Blood|2021Cited by 9